Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Summit Therapeutics said chief operating officer David Roblin had resigned, effective at the end of January.
He would also relinquish the role of chief medical officer and president of R&D.
'David has been instrumental in establishing our leadership position in new mechanism antibiotic development and launching our Phase 3 clinical trials of ridinilazole for the treatment of C. difficile infection,' chief executive Glyn Edwards said.
'We are grateful to David for building a strong team that will continue to advance Summit's important work and wish him all the very best in his future endeavours.'
At 1:57pm: (LON:SUMM) Summit Therapeutics PLC share price was 0p at 22p